ROCKLEDGE, Fla., Jan. 16, 2024 (GLOBE NEWSWIRE) -- LUKE, a trusted leader in healthcare staffing for the U.S. Government, through...
AGOURA HILLS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of...
Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024LOS ANGELES, Jan. 16, 2024...
ROCKVILLE, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics...
MINNEAPOLIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of...
IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO...
Limited Market Release of First Purpose-Built OR Product to Begin in First Half of 2024 SmartFrame OR™ Stereotactic Systemwww.clearpointneuro.com SOLANA...
Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents...
Multiple catalysts anticipated in 2024, including clinical study results for NaviCap™ Targeted Oral Delivery Platform and progress on pharma partnerships...
Oak Ridge, TN, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
-Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024- -Marks the first IND for Aruna’s...
WASHINGTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical...
TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE:PSYG), a clinical-stage life science biotechnology company pioneering...
Innovative process solution provider Single Use Support continues to deliver strong organic growth, supported by an expansion in its employee...
MALVERN, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Positive 12-month safety and efficacy data from ongoing Phase I/II clinical trial of ATSN-101 to be presented at 47th Annual...
The DEKA Intradermal Therapeutic Applicator The DEKA Intradermal Therapeutic Applicator Emergex has entered into an agreement with DEKA Research &...
Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024 Trial to include Schizophrenia validated...
Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including:...
NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing...